Alan M Rathbun1, Leslie R Harrold2, George W Reed3. 1. Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland. Electronic address: arathbun@epi.umaryland.edu. 2. Department of Orthopedics, University of Massachusetts Medical School, Worcester, Massachusetts; CORRONA, Inc., Southborough, Massachusetts. 3. CORRONA, Inc., Southborough, Massachusetts; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts.
Abstract
PURPOSE: Depressive symptoms are common in rheumatoid arthritis (RA) and may affect disease activity and treatment outcomes. The objective of this study was to determine if prevalent depressive symptoms modify biologic treatment response through their effect on RA disease activity. METHODS: RA patients with depressive symptoms, initiating biologic treatment, were identified from a US RA registry sample. Patients with depression were compared with control subjects (ie, those patients with no reports of depressive symptoms at, or before, initiating therapy) in terms of clinical disease activity index (CDAI) remission and low disease activity (LDA), and the changes in the component measures that comprise this scale at 6 and 12 months of follow-up. Inverse probability weighting was used to account for differences in baseline disease severity, concomitant treatment characteristics, and other possible confounders. Logistic and linear regression models estimated differences in response rates and changes in component disease activity measures. FINDINGS: Depressive symptoms were associated with a decreased likelihood of CDAI remission at 6 months (odds ratio, 0.43 [95% CI, 0.19-0.96]) but not at 12 months (odds ratio, 0.83 [95% CI, 0.43-1.60]), and there was no effect on CDAI LDA. Adjusted core component measurement changes showed smaller decreases in global assessment ratings in patients with depressive symptoms; these associations were not statistically significant. IMPLICATIONS: Poorer treatment outcomes among RA patients with depressive symptoms may be a result of higher baseline disease severity. Adjusted estimates indicated symptoms of depression only affected remission at 6 months' follow-up through patient and physician global assessments. Thus, any impact of depressive symptoms during biologic treatment might not be due to a definitive impact on joint swelling and tenderness.
PURPOSE:Depressive symptoms are common in rheumatoid arthritis (RA) and may affect disease activity and treatment outcomes. The objective of this study was to determine if prevalent depressive symptoms modify biologic treatment response through their effect on RA disease activity. METHODS:RApatients with depressive symptoms, initiating biologic treatment, were identified from a US RA registry sample. Patients with depression were compared with control subjects (ie, those patients with no reports of depressive symptoms at, or before, initiating therapy) in terms of clinical disease activity index (CDAI) remission and low disease activity (LDA), and the changes in the component measures that comprise this scale at 6 and 12 months of follow-up. Inverse probability weighting was used to account for differences in baseline disease severity, concomitant treatment characteristics, and other possible confounders. Logistic and linear regression models estimated differences in response rates and changes in component disease activity measures. FINDINGS:Depressive symptoms were associated with a decreased likelihood of CDAI remission at 6 months (odds ratio, 0.43 [95% CI, 0.19-0.96]) but not at 12 months (odds ratio, 0.83 [95% CI, 0.43-1.60]), and there was no effect on CDAI LDA. Adjusted core component measurement changes showed smaller decreases in global assessment ratings in patients with depressive symptoms; these associations were not statistically significant. IMPLICATIONS: Poorer treatment outcomes among RApatients with depressive symptoms may be a result of higher baseline disease severity. Adjusted estimates indicated symptoms of depression only affected remission at 6 months' follow-up through patient and physician global assessments. Thus, any impact of depressive symptoms during biologic treatment might not be due to a definitive impact on joint swelling and tenderness.
Authors: Jaclyn Anderson; Liron Caplan; Jinoos Yazdany; Mark L Robbins; Tuhina Neogi; Kaleb Michaud; Kenneth G Saag; James R O'Dell; Salahuddin Kazi Journal: Arthritis Care Res (Hoboken) Date: 2012-05 Impact factor: 4.794
Authors: Esi Morgan DeWitt; Li Lin; Henry A Glick; Kevin J Anstrom; Kevin A Schulman; Shelby D Reed Journal: Clin Ther Date: 2009-08 Impact factor: 3.393
Authors: Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen Journal: Arthritis Res Ther Date: 2005-04-07 Impact factor: 5.156
Authors: Rosemarie Kobau; Marc A Safran; Matthew M Zack; David G Moriarty; Daniel Chapman Journal: Health Qual Life Outcomes Date: 2004-07-30 Impact factor: 3.186
Authors: Arkady T Manning-Bennett; Ashley M Hopkins; Michael J Sorich; Susanna M Proudman; David J R Foster; Ahmad Y Abuhelwa; Michael D Wiese Journal: Ther Adv Musculoskelet Dis Date: 2022-07-22 Impact factor: 3.625
Authors: Alan M Rathbun; Bryant R England; Ted R Mikuls; Alice S Ryan; Jennifer L Barton; Michelle D Shardell; Marc C Hochberg Journal: J Rheumatol Date: 2020-11-15 Impact factor: 5.346
Authors: Hasan Najah Smesam; Hasan Abbas Qazmooz; Sinan Qayes Khayoon; Abbas F Almulla; Hussein Kadhem Al-Hakeim; Michael Maes Journal: J Pers Med Date: 2022-03-16